Clinical Trial

Safety and Potential Effect of Innovative Treatment by Adjuvant Injection of Stromal Vascular Fraction From Autologous Adipose Tissue of URethral Stenosis With Endoscopic Urethrotomy

Study acronym: SURF
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
SURF is a randomised controlled, parallel group, single blind phase II study designed to assess the safety and potential efficacy of an innovative therapeutic strategy for urethral stenosis based on adjuvant injection of autologous Adipose-Derived Stromal Vascular Fraction of Adipose Tissue (ADSVF) during endoscopic urethrotomy (standard care).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-05-04; most recent amendment 2026-02-03.
Status change: Not Yet Recruiting → Recruiting 2024-03-15
Trial Details
NCT Number NCT05857371
Lead Sponsor Assistance Publique Hopitaux De Marseille
Conditions Urethral Stenosis
Enrollment 20 participants
Start Date 2024-03-13
Primary Completion 2027-11 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-04